SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
PUBLISHED December 12, 2014
Debu Tripathy, editor-in-chief of CURE magazine, reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials called SOFT and TEXT were combined and long-term follow-up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries.
"This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."